Given that PRRX1 deficiency promotes MET and CSCs in breast cancer [18], we reasoned that re-introduction of PRRX1 would reverse MET and CSC-like phenotypes in SIRT1-depleted cells. This evidence concerns the gene SIRT1 and breast carcinoma.